Table 1. Expressions of EGFR family and clinicopathological characteristics of the patients with endometrial cancer.
|
EGFR
|
HER-2
|
HER-4
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Variables | High | Low | P-value | High | Low | P-value | High | Low | P-value |
| Age (years) | |||||||||
| <45 (n=7) | 2 | 5 | 0.5239 | 1 | 6 | 0.1240 | 3 | 4 | 0.7215 |
| ⩾45 (n=56) | 23 | 33 | 25 | 31 | 28 | 28 | |||
| FIGO stage | |||||||||
| I (n=46) | 18 | 28 | 0.8829 | 18 | 28 | 0.5705 | 24 | 22 | 0.4383 |
| II–IV (n=17) | 7 | 10 | 8 | 9 | 7 | 10 | |||
| Lymph-node metastasis | |||||||||
| Negative (n=58) | 24 | 34 | 0.3485 | 25 | 33 | 0.3140 | 28 | 30 | 0.6149 |
| Positive (n=5) | 1 | 4 | 1 | 4 | 3 | 2 | |||
| Depth (myometrial invasion) | |||||||||
| a, b (n=47) | 16 | 31 | 0.1168 | 17 | 30 | 0.1588 | 22 | 25 | 0.5141 |
| c (n=16) | 9 | 7 | 9 | 7 | 9 | 7 | |||
| Histopathological degree of differentiation | |||||||||
| Grades 1 and 2 (n=48) | 17 | 31 | 0.2157 | 20 | 28 | 0.9089 | 22 | 26 | 0.3381 |
| Grade 3 (n=15) | 8 | 7 | 6 | 9 | 9 | 6 | |||
| Menopause | |||||||||
| Peri, pre (n=23) | 6 | 17 | 0.0944 | 6 | 17 | 0.0634 | 10 | 13 | 0.4904 |
| Post (n=40) | 19 | 21 | 20 | 20 | 21 | 19 | |||
| Body mass index | |||||||||
| <25 (n=38) | 17 | 21 | 0.3120 | 18 | 20 | 0.2254 | 22 | 16 | 0.0890 |
| ⩾25 (n=25) | 8 | 17 | 8 | 17 | 9 | 16 | |||
Abbreviations: EGFR=epidermal growth factor receptor; FIGO=International Federation of Gynaecology and Obstetrics.